In­ter­fer­on be­ta-1a can­di­date for COPD ad­vances to PhI­II to test its po­ten­tial against Covid-19

An­oth­er re­pur­posed drug is en­ter­ing Phase III to see if it pass­es the test against Covid-19.

In a small Phase II tri­al, Synair­gen says hos­pi­tal­ized Covid-19 pa­tients who took its in­hal­able in­ter­fer­on be­ta-1a for­mu­la­tion, SNG001, were twice as like­ly to re­cov­er with­in 14 days than pa­tients on a place­bo. CEO Richard Mars­den said the Southamp­ton, UK-based biotech is launch­ing the can­di­date — which was al­ready in de­vel­op­ment for COPD and asth­ma — in­to a 900-per­son Phase III study in the com­ing weeks.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.